Antares Pharma Inc  

(Public, NASDAQ:ATRS)   Watch this stock  
Find more results for ATRS
2.77
-0.20 (-6.73%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.73 - 2.96
52 week 1.82 - 3.20
Open 2.95
Vol / Avg. 1.31M/563,712.00
Mkt cap 364.95M
P/E     -
Div/yield     -
EPS -0.27
Shares 131.74M
Beta 0.53
Inst. own 32%
May 28, 2015
Antares Pharma Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 Antares Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 12, 2015
Q4 2014 Antares Pharma Inc Earnings Release
Mar 12, 2015
Q4 2014 Antares Pharma Inc Earnings Call - Webcast
Mar 2, 2015
Antares Pharma Inc at Cowen Health Care Conference
Feb 25, 2015
Antares Pharma Inc at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -119.89% -132.64%
Operating margin -119.50% -132.49%
EBITD margin - -127.88%
Return on average assets -56.00% -44.58%
Return on average equity -88.21% -62.82%
Employees 93 -
CDP Score - -

Address

SUITE 300, 100 PRINCETON SOUTH
EWING, NJ 8628
United States - Map
+1-609-3593020 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Antares Pharma, Inc. is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company developed both subcutaneous and intramuscular injection technology systems which include Vibex disposable pressure-assisted auto injectors, reusable needle-free injectors and disposable multi-use pen injectors. In addition to the development of OTREXUP, the Company has other internal development programs in process that are conducting clinical studies of Vibex QS T, indicated for testosterone replacement therapy and manufacturing development work for Vibex QS M, indicated for an undisclosed central nervous system (CNS) indication. The Company�s device development programs include: Vibex with Epinephrine, Vibex with Sumatriptan, Disposable pen injector #1 and Disposable pen injector #2.

Officers and directors

Leonard S. Jacob M.D., Ph.D Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Eamonn P. Hobbs President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James E. Fickenscher Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Robert F. Apple CPA Chief Operating Officer, Executive Vice President, President - Parenteral Products Division
Age: 47
Bio & Compensation  - Reuters
Jennifer Evans Stacey Esq. Senior Vice President, General Counsel, Human Resources and Secretary
Bio & Compensation  - Reuters
Robert P. Roche Jr. Director
Age: 59
Bio & Compensation  - Reuters
Marvin Samson Director
Age: 72
Bio & Compensation  - Reuters
Thomas J. Garrity Independent Director
Age: 65
Bio & Compensation  - Reuters
Jacques Gonella Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Anton G. Gueth Independent Director
Age: 57
Bio & Compensation  - Reuters